-
1Academic Journal
Πηγή: Российские биомедицинские исследования, Vol 8, Iss 3 (2024)
Θεματικοί όροι: Medicine (General), низкомолекулярный гепарин, R5-920, острая ишемия конечностей, коронавирусная болезнь 2019, нефракционированный гепарин, тромбэктомия, коронавирус-2 с тяжелым острым респираторным синдромом
Σύνδεσμος πρόσβασης: https://doaj.org/article/c4a26a4b6b624d018f4e4f92c4149703
-
2Academic Journal
Συγγραφείς: J. Kh. Khizroeva, A. S. Antonova, E. S. Egorova, N. A. Makatsariya, Д. Х. Хизроева, А. С. Антонова, Е. С. Егорова, Н. А. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 17, No 6 (2023); 792-800 ; Акушерство, Гинекология и Репродукция; Vol 17, No 6 (2023); 792-800 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: надропарин кальция, assisted reproductive technologies, ART, in vitro fertilization, IVF, low molecular weight heparin, calcium nadroparin, вспомогательные репродуктивные технологии, ВРТ, экстракорпоральное оплодотворение, ЭКО, низкомолекулярный гепарин
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1870/1165; Mascarenhas M.N., Flaxman S.R., Boerma T. et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356. https://doi.org/10.1371/journal.pmed.1001356.; Коротченко О.Е., Гвоздева А.Д., Сыркашева А.Г. Исходы программ вспомогательных репродуктивных технологий у пациенток с привычным невынашиванием беременности в анамнезе. Гинекология. 2017;19(6):43–5. https://doi.org/10.26442/2079-5696_19.6.43-45.; Sunderam S., Kissin D.M., Crawford S.B. et al. Assisted Reproductive Technology Surveillance – United States, 2015. MMWR Surveill Summ. 2018;67(3):1–28. https://doi.org/10.15585/mmwr.ss6703a1.; Choe J., Shanks A.L. In Vitro Fertilization. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK562266/. [Дата обращения: 20.11.2023].; Di Micco P., Russo V., Mastroiacovo D. et al. In vitro fertilization procedures with embryo transfer and their association with thrombophilia, thrombosis and early antithrombotic treatments. J Blood Med. 2020;11:185–90. https://doi.org/10.2147/JBM.S248988.; Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.; D’Uva M., Di Micco P., Strina I.et al. Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy. Biologics. 2008;2(4):897–902. https://doi.org/10.2147/btt.s3852.; Brenner B., Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev. 1997;11(2):72–9. https://doi.org/10.1016/s0268-960x(97)90013-8.; Henriksson P., Westerlund E., Wallen H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632. https://doi.org/10.1136/bmj.e8632.; Грандоне Э. Риск тромбозов и экстракорпоральное оплодотворение. Акушерство, Гинекология и Репродукция. 2022;16(1):90–5. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.286.; Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–7. https://doi.org/10.1093/humrep/det458.; Olausson N., Discacciati A., Nyman A. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: Nationwide cohort study. J Thromb Haemost. 2020;18(8):1965–73. https://doi.org/10.1111/jth.14840.; Ironside E.C., Hotchen A.J. Ovarian hyperstimulation syndrome, the master of disguise? Case Rep Emerg Med. 2015;2015:510815. https://doi.org/10.1155/2015/510815.; Fang L., Li Y., Wang S. et al. TGF-β1 induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome. Exp Mol Med. 2020;52(3):450–60. https://doi.org/10.1038/s12276-020-0396-y.; Rizk B., Aboulghar M., Smitz J., Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3(3):255–66. https://doi.org/10.1093/humupd/3.3.255.; Scotti L., Abramovich D., Pascuali N. et al. Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome. J Steroid Biochem Mol Biol. 2014;144 Pt B:392–401. https://doi.org/10.1016/j.jsbmb.2014.08.013.; Gómez R., Soares S.R., Busso C. et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28(6):448– 57. https://doi.org/10.1055/s-0030-1265670.; Клинические рекомендации – Синдром гиперстимуляции яичников – 2021-2022-2023 (02.09.2021). М.: Министерство здравоохранения Российской Федерации, 2021. 32 c. Режим доступа: http://disuria.ru/_ld/11/1146_kr21N98p1MZ.pdf. [Дата обращения: 20.11.2023].; Khizroeva J., Makatsariya A., Bitsadze V. et al. In vitro fertilization outcomes in women with antiphospholipid antibodies circulation. J Matern Fetal Neonatal Med. 2020;33(12):1988–93. https://doi.org/10.1080/14767058.2018.1535586.; Клинические рекомендации. Венозные осложнения во время беременности и в послеродовом периоде. Акушерская тромбоэмболия. М.: Министерство здравоохранения Российской Федерации, 2022. 99 c. Режим доступа: https://gkb1.chitazdrav.ru/node/9144. [Дата обращения: 20.11.2023].; Greer I.A., Nelson Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–7. https://doi.org/10.1182/blood-2005-02-0626.; Шмаков Р.Г., Вавилова Т.В, Николаева М.Г. и др. Краткие алгоритмы диагностики, профилактики и лечения венозных тромбоэмболических осложнений во время беременности. Акушерство и гинекология. 2022;12 (приложение):4–12.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300.; Bates S.M., Middeldorp S., Rodger M. et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. https://doi.org/10.1007/s11239-015-1309-0.; Chan W.S., Rey E., Kent N.E.; VTE in Pregnancy Guideline Working Group; Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527–53. https://doi.org/10.1016/s17012163(15)30569-7.; American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: Inherited thrombophilias in pregnancy. Obstet Gynecol. 2018;132(1):e18–e34. https://doi.org/10.1097/AOG.0000000000002703.; https://www.gynecology.su/jour/article/view/1870
-
3Academic Journal
Συγγραφείς: Cherniy, V.I., Smirnova, N.N., Egorov, A.A., Kolganova, E.A., Bosko, I.L.
Πηγή: МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; Том 16, № 5 (2020); 45-49
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; Том 16, № 5 (2020); 45-49
EMERGENCY MEDICINE; Том 16, № 5 (2020); 45-49Θεματικοί όροι: венозний тромбоемболізм, онкологічні хворі, профілактика, низькомолекулярний гепарин, 03 medical and health sciences, 0302 clinical medicine, 3. Good health, венозный тромбоэмболизм, онкологические больные, профилактика, низкомолекулярный гепарин, venous thromboembolism, cancer patients, prevention, low molecular weight heparin
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://emergency.zaslavsky.com.ua/article/view/212223
-
4Academic Journal
Συγγραφείς: E. A. Orudzhova, V. O. Bitsadze, M. V. Tretyakova, D. A. Doronicheva, F. Yakubova, Э. А. Оруджова, В. О. Бицадзе, М. В. Третьякова, Д. А. Дороничева, Ф. Якубова
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 16, No 2 (2022); 134-142 ; Акушерство, Гинекология и Репродукция; Vol 16, No 2 (2022); 134-142 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: АФС, FGR, prophylaxis, low molecular weight heparin, LMWH, acetylsalicylic acid, ASA, thrombophilia, antiphospholipid antibodies, APA, antiphospholipid syndrome, APS, ЗРП, профилактика, низкомолекулярный гепарин, НМГ, ацетилсалициловая кислота, АСК, тромбофилия, антифосфолипидные антитела, АФА, антифосфолипидный синдром
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1308/1001; Brosens I., Pijnenborg R., Vercruysse L., Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201. https://doi.org/10.1016/j.ajog.2010.08.009.; Gardosi J., Madurasinghe V., Williams M. et al. Maternal and fetal risk factors for stillbirth:populationbasedstudy. BMJ. 2013;346:f108. https://doi.org/10.1136/bmj.f108.; Malacova E., Regan A., Nassar N. et al. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis. BJOG. 2018;125(2):183–92. https://doi.org/10.1111/1471-0528.14906.; Abou-Nassar K., Carrier M., Ramsay Т., Rodger М.А. The association between antiphospholipid antibodies and placenta-mediated complications: а systematic review and meta-analysis. Thromb Res. 2011;128(1):77–85. https://doi.org/10.1016/j.thromres.2011.02.006.; Гри Ж.К., Макацария А.Д., Бицадзе В.О. и др. Антифосфолипидный синдром и беременность. Акушерство и гинекология. 2018;(10):5–11. https://doi.org/10.18565/aig.2018.10.5-11.; Saccone G., Berghella V., Maruotti G.M. et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525.e1–525.e12. https://doi.org/10.1016/j.ajog.2017.01.026.; Polzin W.J., Kopelman J.N., Robinson R.D. et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol. 1991;78(6):1108–11.; Schjetlein R., Moe N., Wisloff F. et al. Preeclampsia and fetal growth retardation: is there an association with antiphospholipid antibodies? Hypertension in Pregnancy. 2009;17(1):81–92. https://doi.org/10.3109/10641959809072240.; Spegiorin L.C.J.F., Galão E.A., De Godoy J.M.P. et al. Antiphospholipid antibodies and growth retardation in intrauterine development. Prague Med Rep. 2007;108(2):185–90.; Оруджова Е.А. Антифосфолипидные антитела, генетическая тромбофилия и задержка роста плода. Акушерство, Гинекология и Репродукция. 2021;15(6):695–704. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.278.; Heilmann L., von Tempelhoff G.-F., Pollow K. Antiphospholipid syndrome in obstetrics. Clin Appl Thromb Hemost. 2002;9(2):143–50. https://doi.org/10.1177/107602960300900209.; https://www.gynecology.su/jour/article/view/1308
-
5Academic Journal
Συγγραφείς: I. S. Yavelov, K. A. Kaperiz, O. M. Drapkina, И. С. Явелов, К. А. Капериз, О. М. Драпкина
Πηγή: Aterotromboz = Atherothrombosis; № 2 (2021); 94-102 ; Атеротромбоз; № 2 (2021); 94-102 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2021-2
Θεματικοί όροι: ривароксабан, superficial vein thrombosis, fondaparinux, heparin, low molecular weight heparin, parnaparin, rivaroxaban, тромбоз поверхностных вен, фондапаринукс, гепарин, низкомолекулярный гепарин, парнапарин
Περιγραφή αρχείου: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/259/281; Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.J., Harjola V.P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.; Stevens S.M., Woller S.C., Kreuziger L.B., Bounameaux H., Doerschug K., Geersing G.J. et al. Antithrombotic Therapy for VTE Disease Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;S0012-3692(21)01507-5. https://doi.org/10.1016/j.chest.2021.07.055.; Mazzolai L., Ageno W., Alatri A., Bauersachs R., Becattini C., Brodmann M. et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol. 2021;zwab088. https://doi.org/10.1093/eurjpc/zwab088.; Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693–4738. https://doi.org/10.1182/bloodadvances.2020001830.; Kakkos S.K., Manjit G., Baekgaard N., Bauersachs R., Bellmunt-Montoya S., Black S.A. et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg. 2021;61(1):9–82. https://doi.org/10.1016/j.ejvs.2020.09.023.; Decousus H., Prandoni P., Mismetti P., Bauersachs R.M., Boda Z., Brenner B. et al. Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. N Engl J Med. 2010;363(13):1222–1232. https://doi.org/10.1056/NEJMoa0912072.; Duffett L., Kearon C., RodgerM., CarrierM. Treatment of Superficial Vein Thrombosis: A Systematic Review and MetaAnalysis. Thromb Haemost. 2019;119(13):479–489. https://doi.org/10.1055/s-0039-1677793.; Cosmi B., Filippini M., Tonti D., Avruscio G., Ghirarduzzi A., Bucherini E. et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost. 2012;10(6):1026–1035. https://doi.org/10.1111/j.1538-7836.2012.04727.x.; Beyer-Westendorf J., Schellong S.M., Gerlach H., Rabe E., Weitz J.I., Jersemann K. et al. Prevention of thromboembolic complications in patients with superfi cial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017;4(3):e105-e113. https://doi.org/10.1016/S2352-3026(17)30014-5.; Cosmi B., Filippini M., Campana F., Avruscio G., Ghirarduzzi A., Bucherini E. et al. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thromb Res. 2014;133(2):196–202. https://doi.org/10.1016/j.thromres.2013.12.005.; Стойко Ю.М., Кириенко А.И., Илюхин Е.А., Лобастов К.В., Чаббаров Р.Г., Париков М.А. и др. Диагностика и лечение тромбофлебита поверхностных вен конечностей. Рекомендации Ассоциации флебологов России. Флебология. 2019;(2):78–97. https://doi.org/10.17116/flebo20191302178.; https://www.aterotromboz.ru/jour/article/view/259
-
6Academic Journal
Συγγραφείς: S. V. Akinshina, P. K. Genina, V. O. Bitsadze, J. Kh. Khizroeva, V. I. Tsibizova, A. D. Makatsariya, С. В. Акиньшина, П. К. Генина, В. О. Бицадзе, Дж. Х. Хизроева, В. И. Цибизова, А. Д. Макацария
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 15, No 4 (2021); 441-450 ; Акушерство, Гинекология и Репродукция; Vol 15, No 4 (2021); 441-450 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: ривароксабан, pregnancy, low molecular weight heparin, antithrombin III concentrate, rivaroxaban, беременность, низкомолекулярный гепарин, концентрат антитромбина III
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1072/936; Di Minno M.N., Ambrosino P., Ageno W. et al. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res. 2015;135(5):923-32. https://doi.org/10.1016/j.thromres.2015.03.010.; Vossen C.Y., Conard J., Fontcuberta J. et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost. 2005;3(3):459-64. https://doi.org/10.1111/j.1538-7836.2005.01197.x.; Lim W., Eikelboom J.W., Ginsberg J.S. Inherited thrombophilia and pregnancy associated venous thromboembolism. BMJ. 2007;334(7607):1318-21. https://doi.org/10.1136/bmj.39205.484572.55.; Wickstrom K., Edelstam G., Lowbeer C.H. et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest. 2004;64(1):31-40. https://doi.org/10.1080/00365510410003859.; James A.H., Bates S.M., Bauer K.A. et al. Management of hereditary antithrombin deficiency in pregnancy. Thromb Res. 2017;157:41-5. https://doi.org/10.1016/j.thromres.2017.05.017.; Franchi F., Biguzzi E., Martinelli I. et al. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. Thromb Res. 2013;132(2):e152-7. https://doi.org/10.1016/j.thromres.2013.07.003.; Folkeringa N., Brouwer J.L., Korteweg F.J. et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol. 2007;136(4):656-61. https://doi.org/10.1111/j.1365-2141.2006.06480.x.; Mahmoodi B.K., Brouwer J.L., Ten Kate M.K. et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost. 2010;8(6):1193-200. https://doi.org/10.1111/j.1538-7836.2010.03840.x.; Sabadell J., Casellas M., Alijotas-Reig J. et al. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):47-51. https://doi.org/10.1016/j.ejogrb.2009.12.004.; James A.H., Jamison M.G., Brancazio L.R., Myers E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-5. https://doi.org/10.1016/j.ajog.2005.11.008.; James A.H., Konkle B.A., Bauer K.A. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Womens Health. 2013;5:233-41. https://doi.org/10.2147/IJWH.S43190.; Holbrook A., Schulman S., Witt D.M. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S. https://doi.org/10.1378/chest.11-2295.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S-e736S. https://doi.org/10.1378/chest.11-2300.; Kearon C., Akl E.A., Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-52. https://doi.org/10.1016/j.chest.2015.11.026.; Tiede A., Tait R.C., Shaffer D.W. et al. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost. 2008;99(3):616-22. https://doi.org/10.1160/TH07-08-0489.; Rheaume M., Weber F., Durand M., Mahone M. Pregnancy-related venous thromboembolism risk in asymptomatic women with antithrombin deficiency: a systematic review. Obstet Gynecol. 2016;127(4):649-56. https://doi.org/10.1097/AOG.0000000000001347.; Pascual C., Munoz C., Huerta A.R. et al. A new case of successful outcome of pregnancy in a carrier of homozygous type II (L99F) antithrombin deficiency. Blood Coagul Fibrinolysis. 2014;25(1):74-6. https://doi.org/10.1097/MBC.0b013e3283646620.; Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top Guideline No. 37a. Royal College of Obstetricians and Gynaecologists, 2015. 40 p. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf.; ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstet Gynecol. 2018;132(1):e18-e34. https://doi.org/10.1097/AOG.0000000000002703.; ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet Gynecol. 2018;132(1):e1-e17. https://doi.org/10.1097/AOG.0000000000002706.; Bates S.M., Rajasekhar A., Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 201827;2(22):3317-59. https://doi.org/10.1182/bloodadvances.2018024802.; Rogenhofer N., Bohlmann M.K., Beuter-Winkler P. et al. Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. Ann Hematol. 2014;93(3):385-92. https://doi.org/10.1007/s00277-013-1892-0.; Refaei M., Xing L., Lim W. et al. Management of venous thromboembolism in patients with hereditary antithrombin deficiency and pregnancy: case report and review of the literature. Case Rep Hematol. 2017;2017:9261351. https://doi.org/10.1155/2017/9261351.; Skelley J.W., White C.W., Thomason A.R. The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis. 2017;43(1):24-30. https://doi.org/10.1007/s11239-016-1428-2.; Serrao A., Lucani B., Mansour D. et al. Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterr J Hematol Infect Dis. 2019;11(1):e2019044. https://doi.org/10.4084/MJHID.2019.044.; https://www.gynecology.su/jour/article/view/1072
-
7Academic Journal
Συγγραφείς: K. G. Sultangadzhieva, N. N. Babaeva, E. S. Egorova, J. Kh. Khizroeva, M. G. Sultangadzhiev, Х. Г. Султангаджиева, Н. Н. Бабаева, Е. С. Егорова, Д. Х. Хизроева, М. Г. Султангаджиев
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 15, No 5 (2021); 548-561 ; Акушерство, Гинекология и Репродукция; Vol 15, No 5 (2021); 548-561 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: антифибринолитики, RH, bleedings in early pregnancy, antiphospholipid antibodies, АРА, bacterial viral infections during pregnancy, plasminogen activator inhibitor, miscarriage, low molecular weight heparin, LMWH, antifibrinolytics, РГ, кровотечения на ранних сроках беременности, потери беременности, антифосфолипидные антитела, АФА, бактериально-вирусные инфекции при беременности, ингибитор активатора плазминогена, низкомолекулярный гепарин, НМГ
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1132/958; Elsasser D.A., Ananth C.V., Prasad V., Vintzileos A.M.; New JerseyPlacental Abruption Study Investigators. Diagnosis of placental abruption: relationship between clinical and histopathological findings. Eur J Obstet Gynecol Reprod Biol. 2010;148(2):125–30. https://doi.org/10.1016/j.ejogrb.2009.10.005.; Mantoni M., Pedersen J.F. Intrauterine hematoma: an ultrasonic study of threatened abortion. BJOG. 1981;88:47–51. https://doi.org/10.1111/j.1471-0528.1981.tb00936.x.; Jouppila P. Clinical consequences after ultrasonic diagnosis of intrauterine hematoma in threatened abortion. J Clin Ultrasound. 1985;13(2):107–11. https://doi.org/10.1002/jcu.1870130205.; Pearlstone M., Baxi L. Subchorionic hematoma: а review. Obstet Gynecol Surv. 1993;48(2):65–8.; Kurjak A., Schulman H., Zudenigo D. et al. Subchorionic hematomas in early pregnancy: clinical outcome and blood flow patterns. J Matern Fetal Med. 1996;5(1):41–4. https://doi.org/0.1002/(SICI)1520-6661(199601/02)5:13.0.CO;2-Q.; Seki H., Kuromaki K., Takeda S., Kinoshita K. Persistent subchorionic hematoma with clinical symptoms until delivery. Int J Gynaecol Obstet. 1998;63(2):123–8. https://doi.org/10.1016/s0020-7292(98)00153-2.; Sharma G., Kalish R., Chasen S. Prognostic factors associated with antenatal subchorionic echolucencies. Am J Obstet Gynecol. 2003;189(4):994–6. https://doi.org/10.1067/s0002-9378(03)00823-8.; Şükür Y.E., Göç G., Köse O. et al. The effects of subchorionic hematoma on pregnancy outcome in patients with threatened abortion. J Turk Ger Gynecol Assoc. 2014;15(4):239–42.; Peitsidis P., Kadir R.A. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother. 2011;12(4):503– 16. https://doi.org/10.1517/14656566.2011.545818.; Wang D., Luo Z.Y., Yu Z.P. et al. The antifibrinolytic and anti-inflammatory effects of multiple doses of oral tranexamic acid in total knee arthroplasty patients: a randomized controlled trial. J Thromb Haemost. 2018;16(12):2442–53. https://doi.org/10.1111/jth.14316.; Бицадзе В.О., Макацария А.Д. Применение низкомолекулярных гепаринов в акушерской практике. РМЖ. 2000;(18):772–7.; Хизроева Д.Х. Антифосфолипидный синдром и неудачи экстракорпорального оплодотворения. Практическая медицина. 2013;(6):154–60.; De Sancho M.T., Khalid S., Christos P.J. Outcomes in women receiving low-molecular-weight heparin during pregnancy. Blood Coagul Fibrinolysis. 2012;23(8):751–55. https://doi.org/10.1097/MBC.0b013e328358e92c.; Макацария А.Д., Бицадзе В.О. Антифосфолипидный синдром, генетические тромбофилии в патогенезе основных форм акушерской патологии. РМЖ. 2006;(0):2–10.; Макацария А.Д, Серов В.Н., Гри Ж.К. и др. Катастрофический антифосфолипидный синдром и тромбозы. Акушерство и гинекология. 2019;(9):5–14. https://doi.org/10.18565/aig.2019.9.5-14.; Ye Y., Vattai A., Zhang X. et al. Role of plasminogen activator inhibitor type 1 in pathologies of female reproductive diseases. Int J Mol Sci. 2017;18(8):1651. https://doi.org/10.3390/ijms18081651.; Feng L., Allen T.K., Marinello W.P., Murtha A.P. Infection-induced thrombin production: a potential novel mechanism for preterm premature rupture of membranes (PPROM). Am J Obstet Gynecol. 2018;219(1):101. е1–101.е12. https://doi.org/10.1016/j.ajog.2018.04.014.; https://www.gynecology.su/jour/article/view/1132
-
8Academic Journal
Συγγραφείς: Medved, V. I., Danylkiv, O. O.
Πηγή: Actual Problems of Pediatry, Obstetrics and Gynecology; No. 1 (2009) ; Актуальные вопросы педиатрии, акушерства и гинекологии; № 1 (2009) ; Актуальні питання педіатрії, акушерства та гінекології; № 1 (2009) ; 2415-301X ; 2411-4944 ; 10.11603/24116-4944.2009.1
Θεματικοί όροι: thromboembolic vein complications, pregnancy, low-molecular heparin, тромботические осложнения, беременность, низкомолекулярный гепарин, тромботичні ускладнення, вагітність, низькомолекулярний гепарин
Περιγραφή αρχείου: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/act-pit-pediatr/article/view/9655/9313; https://repository.tdmu.edu.ua//handle/123456789/14824
-
9Academic Journal
Συγγραφείς: O. Ostroumova D., I. Goloborodova V., О. Остроумова Д., И. Голобородова В.
Συνεισφορές: The article was published with the financial support of the Pfizer company ., Статья опубликована при финансовой поддержке компании Пфайзер.
Πηγή: Rational Pharmacotherapy in Cardiology; Vol 16, No 3 (2020); 404-414 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 3 (2020); 404-414 ; 2225-3653 ; 1819-6446
Θεματικοί όροι: osteoporosis, osteoporetic fracture, atrial fibrillation, venous thromboembolism, anticoagulants, heparin, low molecular weight heparin, warfarin, direct oral anticoagulants, apixaban, остеопороз, остеопоретический перелом, фибрилляция предсердий, венозные тромбоэмболии, антикоагулянты, гепарин, низкомолекулярный гепарин, варфарин, прямые оральные антикоагулянты, апиксабан
Περιγραφή αρχείου: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2225/1993; Piran S., Schulman S. Management of venous thromboembolism: An update. Thromb J. 2016;14:107-15. DOI:10.1186/s12959-016-0107-z.; Granger C.B., Alexander J.H., McMurray J.J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. DOI:10.1056/NE-JMoa1107039.; Connolly S.J., Eikelboom J., Joyner C., et al. AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17. DOI:10.1056/NEJMoa1007432.; Hylek E.M., Held C., Alexander J.H., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63:2141-7. DOI:10.1016/j.jacc.2014.02.549.; Flaker G.C., Eikelboom J.W., Shestakovska O., et al. Bleeding during treatment with aspirin versus apix-aban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke. 2012;43:3291-7. DOI:10.1161/STROKEAHA.112.664144.; Brandjes D.P., Heijboer H., Buller H.R., et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-9. DOI:10.1056/NEJM199211193272103.; Kelman A., Lane N.E. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. 2005;19:1021-37. DOI:10.1016/j.berh.2005.06.005.; Borgelt L.M., Fixen D.R. Osteoporosis and Osteomalacia. In: Tisdale J.E., Miller D.A., eds. Drug-Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2018: 1119-33.; Jamal S.A., Browner W.S., Bauer D.C., Cummings S.R. Study of Osteoporotic Fractures Research Group. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med. 1998;128:829-32. DOI:10.7326/0003-4819-128-10-199805150-00006.; Tufano A., Coppola A., Contaldi P., et al. Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old? Semin Thromb Hemost. 2015; 41:382-8. DOI:10.1055/s-0034-1543999.; Nelson-Piercy C. Hazards of heparin: Allergy, Heparin-Induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol. 1997;11:489-509. DOI:10.1016/S0950-3552(97)80024-7.; Alban S. Adverse effects of heparin. Handb Exp Pharmacol. 2012;207:211-63. DOI:10.1007/978-3-642-23056-1_10.; Schulman S., Hellgren-Wаngdahl M. Pregnancy, heparin and osteoporosis. Thromb Haemost. 2002;87:180-1.; Barbour L.A., Kick S.D., Steiner J.F., et al. A prospective study of Heparin-Induced osteoporosis in pregnancy using bone densitometry. Am. J. Obstet. Gynecol. 1994;170:862-9. DOI:10.1016/S0002-9378(94)70299-3.; Muir J.M., Andrew M., Hirsh J., et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 1996;88:1314-20. DOI:10.1182/blood.V88.4.1314.bloodjournal8841314.; Muir J.M., Hirsh J., Weitz J.I., et al. A histomorphometric comparison of the effects of heparin and Low-Molecular weight heparin on cancellous bone in rats. Blood. 1997;89:3236-42. DOI:10.1182/blood.V89.9.3236.; Shaughnessy S.G., Young E., Deschamps P., Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995;86:1368-73. DOI:10.1182/blood.V86.4.1368.bloodjournal8641368.; Handschin A.E., Trentz O.A., Hoerstrup S.P., et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg. 2005;92:177-83. DOI:10.1002/bjs.4809.; Osip S.L., Butcher M., Young E., et al. Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro. Thromb Haemost. 2004;92:803-10. DOI:10.1160/TH04-03-0199.; Bhandari M., Hirsh J., Weitz J.I., et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost. 1998;80:413-7. DOI:10.1055/s-0037-1615222.; Irie A., Takami M., Kubo H., et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone. 2007;41:165-74. DOI:10.1016/j.bone.2007.04.190.; Melissari E., Parker C.J., Wilson N.V., et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost. 1992;68: 652-6.; Vik A., Brodin E., Sveinbjornsson B., Hansen J.B. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost. 2007;98:148-54.; Dahlman T.C., Sjoberg H.E., Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. 1994;170:1315-20. DOI:10.1016/S0002-9378(13)90457-9.; Douketis J.D., Ginsberg J.S., Burrows R.F., et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost. 1996;75:254-7.; Nelson-Piercy C., Letsky E.A., de Swiet M. Low-Molecular weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997;176:1062-8. DOI:10.1016/S0002-9378(97)70403-4.; Casele H.L., Laifer S.A. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med. 2000;9:122-5.; Greer I.A., Nelson-Piercy C. Low-Molecular-Weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood. 2005;106:401-7. DOI:10.1182/blood-2005-02-0626.; Lefkou E., Khamashta M., Hampson G., Hunt B.J. Review: Low-Molecular-Weight Heparin-Induced osteoporosis and osteoporotic fractures: A myth or an existing entity? Lupus. 2010;19:3-12. DOI:10.1177/0961203309353171.; Carlin A.J., Farquharson R.G., Quenby S.M., et al. Prospective observational study of bone mineral density during pregnancy: Low molecular weight heparin versus control. Hum Reprod. 2004;19:1211-4. DOI:10.1093/humrep/deh115.; Pettila V., Leinonen P., Markkola A., et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87:182-96. DOI:10.1055/s-0037-1612970.; Tsvetov G., Levy S., Benbassat C., et al. Influence of number of deliveries and total Breast-Feeding time on bone mineral density in premenopausal and young postmenopausal women. Maturitas. 2014;77:249-54. DOI:10.1016/j.maturitas.2013.11.003.; Wawrzynska L., Tomkowski W.Z., Przedlacki J., et al. Changes in bone density during Long-Term administration of Low-Molecular-Weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb. 2003;33:64-7. DOI:10.1159/000073848.; Bernis C. Mineral bone density variation in hemodialysis patients: Nonfractioned heparin (NFH) versus low molecular weight heparin (LMWH). Nephrol Dial Transplant. 1997;12:1789.; Lai K.N., Ho K., Cheung R.C., et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs. 2001;24:447-55. DOI:10.1177/039139880102400708.; Serra R., Buffone G., De Franciscis A., et al. Skin grafting followed by low molecular-weight heparin long-term therapy in chronic venous leg ulcers. Ann Vasc Surg. 2012;26:190-7. DOI:10.1016/j.avsg.2011.04.008.; Grassman E.D., Leya F., Fareed J. et al. A randomized trial of the low Molecular-Weight heparin certoparin to prevent restenosis following coronary angioplasty. J Invasive Cardiol. 2001;13:723-8.; Monreal M., Olive A., Lafoz E., del Rio L. Heparins, coumarin, and bone density. Lancet. 1991;338:706. DOI:10.1016/0140-6736(91)91292-3.; Grzegorzewska A.E., Mlot-Michalska M. Low molecular weight heparins and antiplatelet drugs, and bone mineral density in dialysis patients. Adv Perit Dial. 2008;24:125-31.; Pettila V., Kaaja R., Leinonen P., et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res. 1999;96:275-82. DOI:10.1016/S0049-3848(99)00110-3.; Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168:1265-70. DOI:10.1016/0002-9378(93)90378-V.; Monreal M., Lafoz E., Olive A., et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11. DOI:10.1055/s-0038-1642376.; Gajic-Veljanoski O., Chai W., Prakesh S., Cheung A.M. Effects of Long-Term Low- Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review with MetaAnalysis. J Gen Intern Med. 2016;31:947-57. DOI:10.1007/s11606-016-3603-8.; Karsenty G., Olson E.N. Bone and Muscle Endocrine Functions: Unexpected Paradigms of Inter-Organ Communication. Cell. 2016;164:1248-56. DOI:10.1016/j.cell.2016.02.043.; Price P.A., Williamson M.K. Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone. J Biol Chem. 1981;256:12754-9.; Ferriеre K., Rizzoli R. Anticoagulants and osteoporosis [in French]. Rev Med Suisse. 2007;3: 1508-11.; Pearson D.A. Bone health and osteoporosis: The role of vitamin K and potential antagonism by anticoagulants. Nutr Clin Pract. 2007;22:517-44. DOI:10.1177/0115426507022005517.; Vermeer C. Vitamin K: The effect on health beyond coagulation - An overview. Food Nutr Res. 2012;56:5329. DOI:10.3402/fnr.v56i0.5329.; Cranenburg E.C., Schurgers L.J., Vermeer C. Vitamin K: The coagulation vitamin that became omnipotent. Thromb Haemost. 2007;98:120-5. DOI:10.1160/TH07-04-0266.; Szulc P., Arlot M., Chapuy M.C., et al. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res. 1994;9:1591-5. DOI:10.1002/jbmr.5650091012.; Avgeri M., Papadopoulou A., Platokouki H., et al. Assessment of bone mineral density and markers of bone turnover in children under Long-Term oral anticoagulant therapy. J Pediatr Hematol Oncol. 2008;30:592-7. DOI:10.1097/MPH.0b013e31817541a8.; Rezaieyazdi Z., Falsoleiman H., Khajehdaluee M. et al. Reduced bone density in patients on longterm warfarin. Int J Rheum Dis. 2009;12:130-5. DOI:10.1111/j.1756-185X.2009.01395.x.; Caraballo P.J., Heit J.A., Atkinson E.J., et al. Long-Term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999;159:1750-6. DOI:10.1001/archinte.159.15.1750.; Gage B.F., Birman-Deych E., Radford M.J., et al. Risk of osteoporotic fracture in elderly patients taking warfarin: Results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006;166:241-6. DOI:10.1001/archinte.166.2.241.; Fiordellisi W., White K., Schweizer M. A Systematic Review and Meta-Analysis of the Association Between Vitamin K Antagonist Use and Fracture. J. Gen. Intern. Med 2019;34:304-11. DOI:10.1007/s11606-018-4758-2.; Gigi R., Salai M., Dolkart O., et al. The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res. 2012;53:446-50. DOI:10.3109/03008207.2012.711867.; Somjen D., Katzburg S., Gigi R., et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol. 2013;135:67-70. DOI:10.1016/j.jsbmb.2013.01.006.; Winkler T., Perka C., Matziolis D., Matziolis G. Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts. Open Orthop. J 2011;5:52-8. DOI:10.2174/1874325001105010052.; Morishima Y., Kamisato C., Honda Y., et al. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-os-teocalcin) in rats. Thromb Res. 2013;131:59-63. DOI:10.1016/j.thromres.2012.08.304.; Solayar G.N., Walsh P.M., Mulhall K.J. The effect of a new direct Factor Xa inhibitor on human osteoblasts: An in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord. 2011;12:247. DOI:10.1186/1471-2474-12-247.; Pilge H., Frobel J., Mrotzek S.J. et al. Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: An in-vitro study comparing enoxaparin with rivaroxaban. BMC Musculoskelet. Disord 2016;17:108. DOI:10.1186/s12891-016-0966-2.; Namba S., Yamaoka-Tojo M., Kakizaki R. et al. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels 2017;32:977-82. DOI:10.1007/s00380-017-0950-2.; Abd El Ghafar O.A.M.A., Helal G.K., Abo-Yousef A.M. Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways. Inflam-mopharmacol 2020. DOI:10.1007/s10787-020-00693-8.; Huang H.K., Liu P.P.S., Hsu J.Y et al. Risk of Osteoporosis in Patients ^th Atrial Fibrillation Using NonVitamin K Antagonist Oral Anticoagulants or Warfarin. J Am Heart Assoc 2020;9:e013845. DOI:10.1161/JAHA.119.013845.; Treceno-Lobato C., Jimenez-Serrania M.I., Martinez-Garcia R. et al. New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof. Semin. Thromb. Hemost 2019;45:196-204.; Lau W.C., Chan E.W., Cheung C.L. et al. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients with Nonvalvular Atrial Fibrillation. JAMA 2017;317:1151-8. DOI:10.1001/jama.2017.1363.; Huang H.-K., Liu P.P.-S., Hsu J.-Y. et al. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study. European Heart Journal. 2020;0:1-9. DOI:10.1093/eurheartj/ehz952.; https://www.rpcardio.com/jour/article/view/2225
-
10Academic Journal
Συγγραφείς: A. D. Makatsariya, K. N. Grigoreva, M. A. Mingalimov, V. O. Bitsadze, J. Kh. Khizroeva, M. V. Tretyakova, I. Elalamy, A. S. Shkoda, V. B. Nemirovskiy, D. V. Blinov, D. V. Mitryuk, А. Д. Макацария, К. Н. Григорьева, М. А. Мингалимов, В. О. Бицадзе, Д. Х. Хизроева, М. В. Третьякова, И. Элалами, А. С. Шкода, В. Б. Немировский, Д. В. Блинов, Д. В. Митрюк
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 14, No 2 (2020); 123-131 ; Акушерство, Гинекология и Репродукция; Vol 14, No 2 (2020); 123-131 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: НМГ, COVID-19, coronavirus, disseminated intravascular coagulation, DIC, anticoagulant therapy, low molecular weight heparin, LMWH, коронавирус, синдром диссеминированного внутрисосудистого свертывания, ДВС-синдром, антикоагулянтная терапия, низкомолекулярный гепарин
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/633/798; https://www.gynecology.su/jour/article/view/633/799; Novel Coronavirus – China. World Health Organization. January 12, 2020. Available at: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en. [Accessed: 08.04.2020].; Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. DOI:10.1056/NEJMoa2001017.; Li Q., Guan X., Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207. DOI:10.1056/NEJMoa2001316.; Chan J. F., Yuan S., Kok K.H. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet. 2020;395(10223):514–52. DOI:10.1016/S0140-6736(20)30154-9.; Levi M., van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost. 2014;40(8):874– 80. DOI:10.1055/s-0034-1395155.; Boral B., Williams D., Boral L. Disseminated intravascular coagulation. Am J Clin Pathol. 2016;146(6):670–80. DOI:10.1093/ajcp/aqw195.; Vaught A. J. Critical care for the obstetrician and gynecologist: obstetric hemorrhage and disseminated intravascular coagulopathy. Obstet Gynecol Clin North Am. 2016;43(4):611–22. DOI:10.1016/j.ogc.2016.07.006.; Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. Int J Lab Hematol. 2018;40(Suppl 1):15–20. DOI:10.1111/ijlh.12830.; Moellering R.C., Abbott G. F., Ferraro M. J. Case records of the Massachussets General Hospital. Case 2–2011. A 30-year-old woman with shock after treatment for a furuncle. N Engl J Med. 2011;364(3):266–75. DOI:10.1056/NEJMcpc1003886.; Russell J.A. Management of sepsis. N Engl J Med. 2006;355(16):1699–713. DOI:10.1056/NEJMra043632.; Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI:10.1016/S0140-6736(20)30183-5.; Guan W.J., Ni Z.Y., Hu Y. et al; China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. DOI:10.1056/NEJMoa2002032. [Epub ahead of print].; Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. DOI:10.1111/jth.14768.; Brun-Buisson C., Doyon F., Carlet J. et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;274(12):968–74.; Vanderschueren S., De Weerdt A., Malbrain M. et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871–6. DOI:10.1097/00003246-200006000-00031.; Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145–8. DOI:10.1016/j.cca.2020.03.022.; Wada H., Thachil J., Di Nisio M. et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761–7. DOI:10.1111/jth.12155.; Taylor F. B., Toh C.H., Hoots W. K. et al; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.; Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33. DOI:10.1111/j.1365-2141.2009.07600.x.; Di Nisio M., Baudo F., Cosmi B. et al; Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012;129(5):e177–84. DOI:10.1016/j.thromres.2011.08.028.; Gando S., Levi M., Toh C.H. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2(1):16037. DOI:10.1038/nrdp.2016.38.; Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2(1):67. DOI:10.1186/s40560-014-0065-0.; Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. Mar 27. DOI:10.1111/jth.14817. [Epub ahead of print].; Iba T., Nisio M.D., Levy J.H. et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. DOI:10.1136/bmjopen-2017-017046.; Poterucha T. J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437–44. DOI:10.1160/TH16-08-0620.; https://www.gynecology.su/jour/article/view/633
-
11Academic Journal
Συγγραφείς: A. V. Samorodov, K. N. Zolotukhin, А. В. Самородов, К. Н. Золотухин
Πηγή: Creative surgery and oncology; Том 10, № 2 (2020); 137-142 ; Креативная хирургия и онкология; Том 10, № 2 (2020); 137-142 ; 2076-3093 ; 2307-0501
Θεματικοί όροι: низкомолекулярный гепарин, coronavirus, haemostasis, coronary artery diseases, stents, anticoagulants, venous thrombosis, thromboembolism, DIC syndrome, low-molecular heparin, коронавирус, гемостаз, болезни коронарных артерий, стенты, антикоагулянты, венозный тромбоз, тромбоэмболия, ДВС-синдром
Περιγραφή αρχείου: application/pdf
Relation: https://www.surgonco.ru/jour/article/view/491/399; https://www.surgonco.ru/jour/article/downloadSuppFile/491/42; https://www.surgonco.ru/jour/article/downloadSuppFile/491/43; Ciceri F., Beretta L., Scandroglio A.M., Colombo S., Landoni G., Ruggeri A., et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020 Apr 15. Online ahead of print. PMID: 32294809; Nardelli P., Landoni G. COVID-19-Related Th romboinflammatory Status: MicroCLOTS and Beyond. General Reanimatology. 2020. Online ahead of print. DOI:10.15360/1813-9779-2020-3-0-2; Th achil J., Srivastava A. SARS-2 Coronavirus-Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Th rombosis or Pulmonary Embolism? Semin Th romb Hemost. 2020 May 12. Online ahead of print. DOI:10.1055/s-0040-1712155; Bo Diao, Chenhui Wang, Rongshuai Wang, Zeqing Feng, Yingjun Tan, Huiming Wang, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MedRxiv. 2020.03.04.20031120. DOI:10.1101/2020.03.04.20031120; Savioli F. Is there a rationale for heparin use among severe COVID-19 patients? Einstein (Sao Paulo). 2020;18:eED5758. DOI:10.31744/einstein_journal/2020ed5758; Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020 May 21. Online ahead of print. DOI:10.1056/NEJMoa2015432; Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., et al. High risk of thrombosis in patients with severe SARS- CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98. DOI:10.1007/s00134-020-06062-x; Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., Müller M.C.A., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Th romb Haemost. 2020 May 5. Online ahead of print. DOI:10.1111/jth.14888; Wichmann D., Sperhake J.P., Lütgehetmann M., Steurer S., Edler C., Heinemann A., et al. Autopsy fi ndings and venous thromboembolism in patients with COVID-19. Ann Intern Med. Ann Intern Med. 2020 May 6: M20-2003. DOI:10.7326/M20-2003; Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J., Bondi- Zoccai G., et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352–71. DOI:10.1016/j.jacc.2020.03.031; Spyropoulos A.C., Raskob G.E. New paradigms in venous thromboprophylaxis of medically ill patients. Th romb Haemost. 2017;117(9):1662–70. DOI:10.1160/TH17-03-0168; Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9. DOI:10.1111/jth.14817; Iba T., Nisio M.D., Levy J.H., Kitamura N., Th achil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis defi nition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. DOI:10.1136/bmjopen-2017-017046; Young E. The anti‐inflammatory eff ects of heparin and related compounds. Thromb Res. 2008;122(6):743–52. DOI:10.1016/j.thromres.2006.10.026; Li J.P., Vlodavsky I. Heparin, heparan sulfate and heparanase in infl ammatory reactions. Thromb Haemost. 2009;102(5):823–8. DOI:10.1160/TH09-02-0091; Esmon C.T. Targeting factor Xa and thrombin: impact on coagulation and beyond. Thromb Haemost. 2014;111(4):625–33. DOI:10.1160/TH13-09-0730; Poterucha T.J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti‐infl ammatory eff ects? Th romb Haemost. 2017;117(3):437–44. DOI:10.1160/TH16-08-0620; Морозов К.М., Колбин А.С., Галанкин Т.Л. Сетевой метаанализ эффективности применения парнапарина для профилактики венозных тромбоэмболических осложнений при хирургических вмешательствах. Тромбоз, гемостаз и реология. 2018;(1):31–9. DOI:10.25555/THR.2018.1.0821; Govil D., Pal D. Point-of-care Testing of Coagulation in Intensive Care Unit: Role of Th romboelastography. Indian J Crit Care Med. 2019;23(Suppl 3):S202–6. DOI:10.5005/jp-journals-10071-23253; https://www.surgonco.ru/jour/article/view/491
-
12Academic Journal
Συγγραφείς: Makatsariya, A.D., Макацария, А.Д., Mitriuc, D., Mitryuk, D.V.
Πηγή: Obstetrics, Gynecology and Reproduction 159-162
Θεματικοί όροι: SARS-CoV-2, COVID-19, Coronavirus, disseminated intravascular coagulation, DIC, anticoagulant therapy, low molecular weight heparin, LMWH, коронавирус, синдром диссеминированного внутрисосудистого свертывания, ДВС-синдром, антикоагулянтная терапия, низкомолекулярный гепарин, НМГ
Περιγραφή αρχείου: application/pdf
Relation: https://ibn.idsi.md/vizualizare_articol/111048; urn:issn:23137347
-
13Academic Journal
Συγγραφείς: A. V. Vorobyov, A. D. Makatsariya
Πηγή: Медицинский совет, Vol 0, Iss 2, Pp 79-85 (2016)
Θεματικοί όροι: низкомолекулярный гепарин, thrombosis prophylaxis, low molecular weight heparin, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, гепарин-индуцированная тромбоцитопения профилактика тромбозов, fact, Medicine, oral anticoagulants, heparin-induced thrombocytopenia, пероральные антикоагулянты, ингибиторы xa-фактора
Σύνδεσμος πρόσβασης: https://www.med-sovet.pro/jour/article/download/45/45
https://doaj.org/article/b961a93b89ed4f25a128fd7b8560eca3
https://www.med-sovet.pro/jour/article/view/45
https://cyberleninka.ru/article/n/patogeneticheskie-osobennosti-profilaktiki-trombogemorragicheskih-oslozhneniy-u-onkoginekologicheskih-bolnyh
https://www.med-sovet.pro/jour/article/viewFile/45/45 -
14Report
Θεματικοί όροι: низкомолекулярный гепарин, агрегация тромбоцитов, platelet aggregation, anticoagulant therapy, фактор Виллебранда, нефракционированный гепарин, cardioembolic stroke, von Willebrand factor, кардиоэмболический инсульт, low-molecular-weight heparin, unfractionated heparin, антикоагулянтная терапия
-
15Academic Journal
Συγγραφείς: M. D. Dibirov, A. H. Magdiev
Πηγή: Амбулаторная хирургия, Vol 0, Iss 3-4, Pp 69-76 (2016)
Θεματικοί όροι: тромбоз, диагностика, тромбоэмболия легочной артерии, лечение, низкомолекулярный гепарин, цибор, thrombosis, diagnostics, pulmonary artery thromboembolia, low-molecular heparin, zibor, Surgery, RD1-811
Περιγραφή αρχείου: electronic resource
Relation: https://www.a-surgeon.ru/jour/article/view/63; https://doaj.org/toc/2712-8741; https://doaj.org/toc/2782-2591
Σύνδεσμος πρόσβασης: https://doaj.org/article/431964b91a2a46f98078168105e91126
-
16Academic Journal
Συγγραφείς: D. V. Okley
Πηγή: Clinical pharmacy; Vol. 19 No. 4 (2015); 13-16
Клиническая фармация; Том 19 № 4 (2015); 13-16
Клінічна фармація; Том 19 № 4 (2015); 13-16Θεματικοί όροι: низкомолекулярный гепарин, low molecular weight heparin, катетер-керований тромболізис, нефракціонований гепарин, нефракционированный гепарин, UDC 616-005.6 616.14 616-08, тромболітична терапія, УДК 616-005.6 616.14 616-08, unfractionated heparin, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, гострий тромбоз глибоких вен нижніх кінцівок, острый тромбоз глубоких вен нижних конечностей, низькомолекулярний гепарин, lower-extremity acute deep venous thrombosis, катетер-управляемый тромболизис, thrombolytic therapy, catheter-directed thrombolysis, тромболитическая терапия
Περιγραφή αρχείου: application/pdf; application/msword
-
17Academic Journal
Συγγραφείς: Kyselov, S. M.
Πηγή: Zaporozhye Medical Journal; Vol. 20 No. 4 (2018) ; Запорожский медицинский журнал; Том 20 № 4 (2018) ; Запорізький медичний журнал; Том 20 № 4 (2018) ; 2310-1210 ; 2306-4145
Θεματικοί όροι: myocardial infarction, heart aneurysm, hospital mortality, vital statistics, anticoagulants, unfractionated heparin, low-molecular-weight heparin, инфаркт миокарда, аневризма сердца, госпитальная летальность, демографическая статистика, антикоагулянты, нефракционированный гепарин, низкомолекулярный гепарин, інфаркт міокарда, аневризма серця, госпітальна летальність, демографічна статистика, антикоагулянти, нефракціонований гепарин, низькомолекулярний гепарин
Περιγραφή αρχείου: application/pdf
Relation: http://zmj.zsmu.edu.ua/article/view/135747/136121; http://zmj.zsmu.edu.ua/article/view/135747
Διαθεσιμότητα: http://zmj.zsmu.edu.ua/article/view/135747
-
18Academic Journal
Συγγραφείς: V. B. Zubenko, В. Б. Зубенко
Πηγή: Obstetrics, Gynecology and Reproduction; Vol 12, No 1 (2018); 17-22 ; Акушерство, Гинекология и Репродукция; Vol 12, No 1 (2018); 17-22 ; 2500-3194 ; 2313-7347
Θεματικοί όροι: ведение беременности, thrombophilia, hemostasis disorders, prevention of pregnancy complications, low molecular weight heparin, pregnancy management, тромбофилия, нарушения гемостаза, профилактика осложнений беременности, низкомолекулярный гепарин
Περιγραφή αρχείου: application/pdf
Relation: https://www.gynecology.su/jour/article/view/466/659; Медянникова И.В. Особенности течения беременности и родов при аномалиях плацентации. Вестник Кузбасского научного центра. 2007; 4: 86-7.; Coulam C.B., Jeyendran R.S., Fishel L.A., Roussev R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online. 2006; 12 (3): 322 7.; Медянникова И.В. Акушерские и перинатальные аспекты аномальной плацентации: Автореф. дис. канд. мед. наук. Пермь. 2007: 23 с.; Бицадзе В.О. Патогенез, принципы диагностики и профилактики осложнений беременности, обусловленных тромбофилией: Автореф. дис. докт. мед. наук. М. 2004: 46 с.; Макацария А.Д., Бицадзе В.О. Тромбофилии и противотромботическая терапия в акушерской практике. М.: Триада-Х. 2003: 904 с.; Макацария А.Д., Бицадзе В.О., Акиньшина С.В. Тромбозы и тромбоэмболии в акушерско- гинекологической клинике: молекулярногенетические механизмы и стратегия профилактики тромбоэмболических осложнений: руководство для врачей. М.: МИА. 2007: 1064 с.; Qublan H., Amarin Z., Dabbas M. et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb). 2008; 11: 246-53.; Achache H., Revel A. Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Updatе. 2006; 12 (6): 731-46.; Azem F., Many A., Ben Ami I. et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod. 2004; 19: 368-70.; Berker B., Taskin S., Kahraman K., Taskin E.A., Atabekoglu C., Sonmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasirandomized, controlled study. Fertil Steril. 2011; 95 (8): 2499-502.; Assou S., Boumela I., Haouzi D. et al. Dynamic changes in gene expression during human early embryo development: from fundamental aspects to clinical applications. Hum Reprod Updatе. 2011; 17 (2): 272-90.; Баймурадова С.М. Патогенез, принципы диагностики, профилактики и терапии синдрома потери плода, обусловленного приобретенными и генетическими дефектами гемостаза: Автореф. дис. докт. мед. наук. М. 2007: 46 с.; Redline R.W. Thrombophilia and placental pathology. Clin Obstet Gynecol. 2006; 49 (4): 885-94.; Gogia N., Machin G.A. Maternal thrombophilias are associated with specific placental lesions. Pediatr Dev Pathol. 2008; 11 (6): 424-9.; https://www.gynecology.su/jour/article/view/466
-
19Academic Journal
Συγγραφείς: E. V. Moroz, E. N. Artemkin, E. V. Kryukov, V. A. Chernetsov, Е. В. Мороз, Э. Н. Артемкин, Е. В. Крюков, В. А. Чернецов
Πηγή: General Reanimatology; Том 14, № 3 (2018); 15-26 ; Общая реаниматология; Том 14, № 3 (2018); 15-26 ; 2411-7110 ; 1813-9779 ; 10.15360/1813-9779-2018-3
Θεματικοί όροι: низкомолекулярный гепарин, digestive system, bleeding, erosive esophagitis, erosions, ulcers, H.pylori, risk factors, antithrombotic therapy, aspirin, warfarin, clopidogrel, dabigatran, rivaroxaban, low-molecular heparin, пищеварительная система, кровотечения, эрозивный эзофагит, эрозии, язвы, факторы риска, антитромботическая терапия, аспирин, варфарин, клопидагрел, дабигатран, ривароксабан
Περιγραφή αρχείου: application/pdf
Relation: https://www.reanimatology.com/rmt/article/view/1687/1219; https://www.reanimatology.com/rmt/article/view/1687/1220; Мороз Е.В., Каратеев А.Е., Крюков Е.В., Чернецов В.А. Желудочнокишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Науч.-практ. ревматология. 2017; 55 (6): 675-684. DOI:10.14412/1995-4484-2017-675-684; Weitz J.I., Jaffer I.H., Fredenburgh J.C. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000Res. 2017; 6: 985. DOI:10.12688/f1000research.11174.1. PMID: 28713563; Deutsch D., Boustière C., Ferrari E., Albaladejo P., Morange P.E., Benamouzig R. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap. Adv. Gastroenterol. 2017; 10 (6): 495-505. DOI:10.1177/1756283X17702092. PMID: 28567119; Hsu P.I., Tsai T.J. Epidemiology of upper gastrointestinal damage associated with low-dose aspirin. Curr. Pharm. Des. 2015; 21 (35): 5049-5055. DOI:10.2174/1381612821666150915104800. PMID: 26369688; Cheung K.S., Leung W.K. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J. Gastroenterol. 2017; 23 (11): 1954-1963. DOI:10.3748/wjg.v23.i11.1954. PMID: 28373761; Eikelboom J.W., Wallentin L., Connolly S.J., Ezekowitz M., Healey J.S., Oldgren J., Yang S., Alings M., Kaatz S., Hohnloser S.H., Diener H.C., Franzosi M.G., Huber K., Reilly P., Varrone J., Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123 (21): 2363-2372. DOI:10.1161/CIRCULATIONAHA.110.004747. PMID: 21576658; Здравоохранение в России. 2017. Статистический сборник Росстата. М.; 2017: 170.; Загородний Н.В. Некоторые статистические данные об эндопротезировании тазобедренного и коленного суставов в РФ за 2014–2015 годы. Лидер мнений. 2017; 3: 12-18.; Thomopoulos K.C., Mimidis K.P., Theocharis G.J., Gatopoulou A.G., Kartalis G.N., Nikolopoulou V.N. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J. Gastroenterol. 2005; 11 (9): 1365-1368. DOI:10.3748/wjg.v11.i9.1365. PMID: 15761977; Rubin T.A., Murdoch M., Nelson D.B. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest. Endosc. 2003; 58 (3): 369-373. DOI:10.1067/S0016-5107(03) 00010-5. PMID: 14528210; Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска. Тер. архив. 2008; 80 (5): 62–66. PMID: 18590118; Каратеев А.Е. Лечение бисфосфанатами и патология пищевода. Совр. ревматология. 2010; 3: 73-79.; Wood M., Shaw P. Pradaxa-induced esophageal ulcer. BMJ Case Rep. 2015; 2015: pii: bcr2015211371. DOI:10.1136/bcr-2015-211371. PMID: 26452739; Singh S., Savage L., Klein M., Thomas C. Severe necrotic oesophageal and gastric ulceration associated with dabigatran. BMJ Case Rep. 2013; 2013: pii: bcr2013009139. DOI:10.1136/bcr-2013-009139. PMID: 23608859; Izumikawa K., Inaba T., Mizukawa S., Kawai Y., Sakakihara I., Ishikawa S., Miyoshi M., Wato M., Kawai K. Two cases of dabigatran-induced esophageal ulcer indicating the usefulness of drug administration guidance. Nihon Shokakibyo Gakkai Zasshi. 2014; 111 (6): 1096-1104. PMID: 24898488; Scheppach W., Meesmann M. Exfoliative esophagitis while taking dabigatran. Dtsch. Med. Wochenschr. 2015; 140 (7): 515-518. DOI:10.1055/s-0041-101313. PMID: 25826037; Okada M., Okada K. Exfoliative esophagitis and esophageal ulcer induced by dabigatran. Endoscopy. 2012; 44 Suppl 2 UCTN: E23-E24. DOI:10.1055/s-0031-1291503. PMID: 22396259; Toya Y., Nakamura S., Tomita K., Matsuda N., Abe K., Abiko Y., Orikasa S., Akasaka R., Chiba T., Uesugi N., Sugai T., Matsumoto T. Dabigatraninduced esophagitis: the prevalence and endoscopic characteristics. J. Gastroenterol. Hepatol. 2016; 31 (3): 610-614. DOI:10.1111/jgh.13024. PMID: 26102078; Vicente V., Martín A., Lecumberri R., Coll-Vinent B., Suero C., GonzálezPorras J.R., Marco P., Mateo J., Roldán V., Soulard S., Crespo C., Camats M.; Grupo DECOVER. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal). Emergencias. 2017; 29 (1): 18-26. PMID: 28825264; Lanas-Gimeno A., Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin. Drug Saf. 2017; 16 (6): 673-685. DOI:10.1080/14740338.2017.1325870. PMID: 28467190; Albaladejo P., Samama C.M., Sié P., Kauffmann S., Mémier V., Suchon P., Viallon A., David J.S., Gruel Y., Bellamy L., de Maistre E., Romegoux P., Thoret S., Pernod G., Bosson J.L.; GIHP-NACO Study Group. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology. 2017; 127 (1): 111-120. DOI:10.1097/ALN.0000000000001631. PMID: 28410272; Lauffenburger J.C., Rhoney D.H., Farley J.F., Gehi A.K., Fang G. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy. 2015; 35 (6): 560-568. DOI:10.1002/phar.1597. PMID: 26044889; Каратеев А.Е., Цурган А.В., Мороз Е.В. Helicobacter pylori у больных ревматическими заболеваниями: частота инфицированности и оценка эффективности альтернативной схемы эрадикационной терапии. РМЖ. 2017; 25 (17): 1220-1224.; Каратеев А.Е., Мороз Е.В., Цурган А.В., Гонтаренко Н.В. Нужно ли проводить эрадикацию Helicobacter pylori у больных с эрозиями и язвами, возникшими на фоне терапии нестероидными противовоспалительными препаратами? Рос. журн. гастроэнтерол., гепатол., колопроктол. 2016; 26 (6): 5-17. DOI:10.22416/1382-4376-2016-6-5-17; Andersen I.B., Jørgensen T., Bonnevie O., Grønbaek M., Sørensen T.I. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study. Epidemiology. 2000; 11 (4): 434-439. DOI:10.1097/00001648-200007000-00012. PMID: 10874551; Kang J.M., Kim N., Lee B.H., Park H.K., Jo H.J., Shin C.M., Lee S.H., Park Y.S., Hwang J.H., Kim J.W., Jeong S.H., Lee D.H., Jung H.C., Song I.S. Risk factors for peptic ulcer bleeding in terms of Helicobacter pylori, NSAIDs, and antiplatelet agents. Scand. J. Gastroenterol. 2011; 46 (11): 1295-1301. DOI:10.3109/00365521.2011.605468. PMID: 21815866; Strate L.L., Singh P., Boylan M.R., Piawah S., Cao Y., Chan A.T. A prospective study of alcohol consumption and smoking and the risk of major gastrointestinal bleeding in men. PLoS One. 2016; 11 (11): e0165278. DOI:10.1371/journal.pone.0165278. PMID: 27824864.; https://www.reanimatology.com/rmt/article/view/1687
-
20Academic Journal
Συγγραφείς: S. V. Akinshina, A. D. Makatsaria, V. O. Bitsadze
Πηγή: Медицинский совет, Vol 0, Iss 9, Pp 84-89 (2014)
Θεματικοί όροι: репродуктивные технологии, тромбоэм-болические осложнения, профилактика, низкомолекулярный гепарин, бемипарин, reproductive technologies, thromboembolic complications, prevention, low-molecular-weight heparin, bemiparin, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/637; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/ded306ff5996435ba82f5a47698e6abc